Recent advances in the treatment of localized rectal cancer

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 220-224

  Bosset, Jean François ^a   Nguyen, France ^b   Bosset, Mathieu ^b   Servagi Vernat, Stéphanie ^b   Schipman, Benjamin ^b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PREOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REVIEW; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME; MULTIMODALITY CANCER THERAPY; RECTUM TUMOR;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; RECTAL NEOPLASMS;

EID: 58149134999     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0034-7     Document Type: Review

References (27)

1. Burton S, Brown G, Daniels IR, et al.: MRI directed multidisciplinary team preoperative treatment strategy: The way to eliminate positive circumferential margins? Br J Cancer 2006, 94:351-357.
2. Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
3. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997, 336:980-987.
4. Bosset JF, Collette L, Calais G, et al.: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
5. Bosset JF, Calais G, Daban A, et al.: Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: Assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer 2004, 40:219-224.
6. Bosset JF, Calais G, Mineur L, et al.: Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005, 23:5620-5627.
7. Gerard JP, Conroy T, Bonnetain F, et al.: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006, 28:4620-4625.
8. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al.: Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.
9. Bosset JF: DistaS rectal cancer: sphincter-sparing is also a challenge for the radiation oncologist. Radiother Oncol 2006, 80:1-3.
10. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
11. Dunst J, Reese T, Sutter T, et al.: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002, 20:3983-3991.
12. Fernandez-Martos C, Aparicio J, Bosch C, et al.: Preoperative oral uracil, tegafur and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-up. J Clin Oncol 2004, 22:3016-3022.
13. Das P, Lin EH, Bhatia S, et al.: Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 2006, 66:1378-1383.
14. Crane CH, Sargent DJ: Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: How much data do we need? J Clin Oncol 2004, 22:2978-2981.
15. Hartley A, Ho KF, McConkey C, et al.: Pathological complete response following preoperative chemoradiotherapy in rectal cancer: Analysis of phase II/III trials. Br J Radiol 2005, 78:934-938.
16. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al.: A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005, 93:993-998.
17. Glynne-Jones R, Falk S, Maughan TS, et al.: A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group study. Br J Cancer 2007, 96:551-558.
18. Willett CG, Boucher Y, Duda DG, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
19. Chau I, Brown G, Cunningham D, et al.: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006, 24:668-674.
20. Collette L, Bosset JF, den Dulk M, et al.: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386.
21. Glynne-Jones R, Mawdsley S, Pearce T, et al.: Alternative clinical end points in rectal cancer: Are we getting closer? Ann Oncol 2006, 17:1239-1246.
22. Rödel C, Martus P, Papadoupolos T, et al.: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23:8688-8696.
23. Kim C, Anne PR, Michel E, et al.: Impact of pre-treatment size and lymph nodes on pathological complete response and survival in a prospective trial of chemoradiation. Int J Radiat Oncol Biol Phys 2005, 63(Suppl 164): Abstract 1034.
24. Habr-Gama A, Perez RO, Nadalin W, et al.: Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005, 9: 90-99; discussion 99-101.
25. Habr-Gama A: Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006, 8(Suppl 3):21-24.
26. O'Neill BD, Brown G, Heald RJ, et al.: Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007, 8:625-633.
27. Ghadimi BM, Grade M, Difilippantonio MJ, et al.: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23:1826-1838.